FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Resources - All Kinds, Realm US, Authority Hl7

19,360 resources (JSON | CSV)

Type:
Text: Package: Only Show Used

By Version

 

Start Prev Rows 7800 - 8000 Next

PackageVersionIdentityName/TitleStatusFMMWGDateUsage #
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1087.jsonEsophageal achalasiaactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1088.jsonET propanolol or primidoneactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1089.jsonET topiramate alprazolam or gabapentinactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.109.jsonCKD stage4above I10active2024-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1090.jsonBlephraospasm SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1091.jsonBlepharospasm I10active2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1092.jsonBlepharospasmactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1093.jsonStrabismus SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1094.jsonStrabismus I10active2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1095.jsonStrabismusactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1096.jsonOveractive bladder SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1097.jsonOveractive bladder I10active2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1098.jsonOveractive bladderactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1099.jsonMovement disorders SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.110.jsonCKD stage4above SCTactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1100.jsonMovement disorders I10active2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1101.jsonMovement disordersactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1102.jsonLateral epicondylitis SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1103.jsonLateral epicondyltisis I10active2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1104.jsonLateral epicondylitisactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1105.jsonPlantar fasciitis SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1106.jsonPlantar fasciitis I10active2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1107.jsonPlantar fasciititsactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1108.jsonCardiac CT SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1109.jsonCardiac CT CPTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.111.jsonCKD stage4aboveactive2024-06
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1111.jsonCardiac CTactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1112.jsonCardiac MRI SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1113.jsonCardiac MRI CPTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1114.jsonCardiac MRIactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1115.jsonCT Angiography of Coronary Artery SCTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1116.jsonCT Angiography of Coronary Artery CPTactive2025-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.1117.jsonCT Angiography of Coronary Arteryactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.120.jsonDiabetic ketoacidosis SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.121.jsonDiabetic ketoacidosisactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.146.jsonLong Acting Muscarinic Antagonists (LAMA)active2023-113
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.159.jsonconditions_COPD I10active2024-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.175.jsonAsthmaactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.184.jsonDigTx Virtual Reality Contraindications Visual Impairmentactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.186.jsonBeta blockers GDMT for heart failureactive2023-12
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.188.jsonmedications_heart failureactive2024-12
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.197.jsonBlood (Serum and Plasma) Potassiumactive2023-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.214.jsonType 1 Diabetes Mellitus SCTactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.238.jsonMRA mineralocorticoid receptor antagonistsactive2024-101
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.244.jsonMRA Mineralocorticoid Receptor Antagonist Allergyactive2023-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.260.jsonUACR SCTactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.263.jsonPregnancy I10active2023-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.281.jsonStatins Allergy SCTactive2023-032
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.282.jsonStatin Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.314.jsonrelatedconditions_hyperlipidemia I10active2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.337.jsonMigraine I10active2023-031
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.34.jsonBlood pressure panelactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.35.jsonSystolic Blood Pressureactive2024-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.367.jsonTrandolaprilactive2024-12
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.369.jsonCandesartanactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.377.jsonValsartanactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.397.jsoneGFRactive2025-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.412.jsonStatin Moderate Intensityactive2024-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.415.jsonLDL Cholesterolactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.43.jsonUrinalysisactive2024-02
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.434.jsonInsulinactive2025-022
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.437.jsonTZD Thiazolidinedionesactive2025-053
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.438.jsonmedications_T2DMactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.440.jsonrelatedconditions_T2DM SCTactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.442.jsonBlood Glucoseactive2024-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.459.jsonLiver canceractive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.47.jsonACE inhibitor allergy SCTactive2022-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.474.jsonAllergy to Tdap Vaccineactive2023-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.475.jsonAllergy to Td Vaccineactive2023-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.481.jsonmedications_hypertensionactive2024-12
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.492.jsonInhaled Corticosteroids Allergyactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.498.jsonMetformin AllergyIntolerance SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.508.jsonAbdominal aortic imaging CPTactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.517.jsonHemoglobin A1cactive2024-03
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.518.jsonDrug hypersensitivity I10active2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.519.jsonDrug hypersensitivity SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.520.jsonDrug hypersensitivityactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.521.jsonDiabetic Kidney Disease I10active2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.523.jsonDiabetic kidney diseaseactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.524.jsonChronic Hepatitis SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.525.jsonChronic Hepatitisactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.527.jsonOCS_Prednisoneactive2024-122
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.531.jsonAnti IgE Medicationsactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.532.jsonIL5 Antagonistsactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.533.jsonMast cell stabilizers for asthmaactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.534.jsonVasospastic disease I10active2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.535.jsonVasospastic disease SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.536.jsonVasospastic diseaseactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.537.jsonHemiplegic and basilar migraine I10active2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.538.jsonHemiplegic and basilar migraine SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.539.jsonHemiplegic and basilar migraineactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.540.jsonPeptic ulcer disease I10active2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.541.jsonPeptic ulcer disease SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.542.jsonPeptic ulcer diseaseactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.544.jsonBleeding disorder I10active2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.545.jsonBleeding disorder SCTactive2023-071
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.548.jsonElectronic cigarettes or Vapingactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.549.jsonBleeding disorderactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.552.jsonTriptansactive2023-082
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.553.jsonCGRP receptor antagonistsactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.554.jsonDitansactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.555.jsonErgotsactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.556.jsonMigraine specific NSAIDsactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.557.jsonOTC migraine analgesicsactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.559.jsonmedications_migraine_acuteactive2023-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.560.jsonrelatedconditions_migraine I10active2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.561.jsonconditions_migraineactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.562.jsonrelatedconditions_migraine SCTactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.563.jsonrelatedconditions_migraineactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.564.jsonTriptan Allergy Intolerance SCTactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.565.jsonTriptan Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.566.jsonIschemic bowel disease SCTactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.567.jsonIschemic bowel disease I10active2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.568.jsonIschemic bowel diseaseactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.573.jsonconditions_hyperlipidemia I10active2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.574.jsonconditions_hyperlipidemia SCTactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.575.jsonconditions_hyperlipidemiaactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.578.jsonPIM_Schedule Vactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.580.jsonPIM_Acarboseactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.582.jsonPIM_Dulaglutideactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.583.jsonPIM_Glimepirideactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.585.jsonPIM_Glucophageactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.587.jsonPIM_Glucovanceactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.588.jsonGlyburide PIMactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.590.jsonAlpha glucosidase inhibitorsactive2023-082
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.592.jsonAzotemiaactive2023-08
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.594.jsonIntolerance to ARB SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.595.jsonICS Lowactive2024-121
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.596.jsonICS Mediumactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.597.jsonICS Highactive2023-081
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.598.jsonLow Dose ICS Formoterolactive2024-051
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.600.jsonPIM_Vitamin B12 Level_LOINCactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.601.jsonPIM_Vitamin B12 Level_CPTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.604.jsonPIM_Glyburideactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.605.jsonPIM_Pioglitazoneactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.606.jsonPIM_Semaglutideactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.607.jsonPIM_Linagliptinactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.609.jsonMacrolide_Azithromycinactive2023-082
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.61.jsonSecondary antihypertensivesactive2023-07
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.610.jsonLong Acting Beta Agonists (LABA) Non_Formoterolactive2023-111
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.612.jsonWolff Parkinson White SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.613.jsonWolff Parkinson White I10active2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.614.jsonWolff Parkinson Whiteactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.615.jsonmedications_Asthmaactive2024-12
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.619.jsonICS_LABA_LAMAactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.620.jsonLow Dose ICS_LABA_Non Formoterolactive2024-061
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.621.jsonMedium ICS_LABA Non Formoterolactive2023-111
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.623.jsonLAMA Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.624.jsonLABA Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.625.jsonBetaBlock NonCS Secondary Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.626.jsonEplerenone Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.627.jsonSpironolactone Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.628.jsonSGLT2 Inhibitors Allergy SCTactive2024-042
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.629.jsonPIM_Refill_Request_Antilipemics_LFTsactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.630.jsonAngiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.631.jsonPneumococcal Vaccine Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.632.jsonMeglitinides Allergy SCTactive2024-042
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.633.jsonDPP4i Allergy SCTactive2024-042
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.635.jsonAlpha_glucosidase inhibitors allergy SCTactive2023-092
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.636.jsonGlucagon_Like Peptide 1 Receptor Agonist (GLP1RA) Allergy SCTactive2023-092
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.637.jsonInsulins Allergy SCTactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.638.jsonTZD Allergy SCTactive2024-042
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.639.jsonT2DM_Medications Allergy SCTactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.642.jsonT2DM_Medications Allergy RXNORMactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.643.jsonT2DM_Medications Allergy SNOMEDactive2023-091
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.646.jsonT2DM_Medication Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.647.jsonStatins Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.649.jsonACE Inhibitors Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.650.jsonARB Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.652.jsonLong Acting Muscarinic Antagonists (LAMA) Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.653.jsonLong Acting Beta Agonists (LABA) Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.654.jsonBetaBlocker NonCS Secondary Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.656.jsonMRA Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.657.jsonEplerenone Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.658.jsonSpironolactone Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.659.jsonSGLT2i Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.660.jsonAngiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.661.jsonTetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.665.jsonTetanus toxoid, diphtheria (Td) Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.666.jsonHuman Papillomavirus (HPV) vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.667.jsonHerpes Zoster Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.670.jsonPneumococcal Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.671.jsonInhaled Corticosteroids(ICS) Allergy Intoleranceactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.672.jsonLABA(Formoterol only)active2023-111
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.674.jsonPIM_Tirzepatideactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.675.jsonGLP1RA Allergy Intoleranceactive2025-04
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.676.jsonPIM_Diabetes_Testing_Suppliesactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.677.jsonPIM_H2_Antagonistsactive2023-09
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.678.jsonSGLT2i DM CKDactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.679.jsonSGLT2i DM ASCVDactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.683.jsonOIA_Gout_Medicationsactive2025-05
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.684.jsonGlumetzaSubstitutionactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.685.jsonMetforminER500mgactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.686.jsonPIM_Metforminactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.687.jsonPIM_Glipizideactive2024-101
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.689.jsonPIM_Glipizide_Glyburide_Glimepirideactive2024-11
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.690.jsonPIM_Insulin_Meglitinidesactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.691.jsonPIM_Glyxambiactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.692.jsonPIM_Farxigaactive2023-10
us.nlm.vsacR4ValueSet/ValueSet-2.16.840.1.113762.1.4.1078.693.jsonPIM_Invokanaactive2023-101